AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01648348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02398903 — intervention group
Intervention type: OTHER
Intervention: DXA and impedancemetry
Description: Body composition by DXA and impedancemetry
Study NCT01648348 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01648348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01648348 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01648348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01648348 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02532556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (Digitimer)
Description: Stimulation with Digitimer (DS7A HV, Digitimer Ltd, UK) over motor point of muscle in protocol. 1Hz, pulse duration 1ms, maximum compliance voltage 200V. Current set to twice motor threshold
Study NCT06022835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate-gel (CHG) Dressing
Description: Participants used Tegaderm™ CHG dressing for 4 months. The dressing was changed every seven days or soiled.
Study NCT02674217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: autologous transplant using non-frozen peripheral blood stem cells
Study NCT02925273 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: palmar grasp without dorsal stimulation
Description: The patient will then be asked to keep the arms at 90 degrees and the researcher will slightly stroke palm and fingers of both hands of the patient simultaneously. After completion of each technique, the presence or absence of the response will be noted. In addition, the prominence of the response on the rating scale will be obtained as explained below.~The scaling of the grasp response is as followed:~1. Flexion at the distal interphalangeal joint of the hand~2. Flexion at the proximal interphalangeal joint of the hand~3. Flexion at the metacarpal-phalangeal joint of the hand
Study NCT02925273 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard palmar grasp test with dorsal stimulation
Description: The patient will be asked to put their arms at 90 degrees and the researcher will hold one hand at the wrist and dorsum of the palm and lightly stroke the palm and fingers. The patient will be instructed to relax hands and not hold on while doing the grasp and see if the response persists. The same technique will be repeated for the patient's other hand.
Study NCT05120011 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: L-carnitine-L-tartrate
Study NCT01669798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: PO 200mg BID
Study NCT03390868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based training for staff
Description: This web-based training program is focusing on strengthening the carers' communication skills. Video lectures on the definitions, characteristics and causes of challenging behavior will be given. Video lectures will also be given on the importance of the carers' views on their values, emotions, abilities and attitude towards people with intellectual disabilities and on the impact that workplace culture and environmental factors have on the quality of interactions. The program also includes written cases that gives the participants opportunities to reflect upon approaches supporting a successful interaction. It also covers factors to consider when mental illness and challenging behavior occur. The time to complete the web-based training program is estimated at approximately ten hours.
Study NCT03390868 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Web-based training for staff
Description: This web-based training program is focusing on strengthening the carers' communication skills. Video lectures on the definitions, characteristics and causes of challenging behavior will be given. Video lectures will also be given on the importance of the carers' views on their values, emotions, abilities and attitude towards people with intellectual disabilities and on the impact that workplace culture and environmental factors have on the quality of interactions. The program also includes written cases that gives the participants opportunities to reflect upon approaches supporting a successful interaction. It also covers factors to consider when mental illness and challenging behavior occur. The time to complete the web-based training program is estimated at approximately ten hours.
Study NCT01177423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental anesthesia
Description: Pulpal and periapical molar and premolar sedation is randomly managed among studied population and Pulp-tester measures anesthesia minute by minute.
Study NCT05120011 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-leucine
Description: L-leucine
Study NCT05120011 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-leucine
Description: L-leucine
Study NCT04109911 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented oyster extract
Description: Fermented oyster extract 1,200 mg/day for 12 weeks
Study NCT04109911 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03636321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: living donor liver transplantation with internal biliary stent
Description: living donor liver transplantation without internal biliary stent
Study NCT03636321 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: living donor liver transplantation with internal biliary stent
Description: living donor liver transplantation without internal biliary stent
Study NCT02354586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Study NCT00003520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage IV Kidney Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT02490423 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nudges Intervention
Description: The intervention arm will employ standard cardiovascular clinical care plus the combination of the MoBe Maps Patient Activation Platform with the Intermountain Risk Score to personalize and deliver motivational nudges to each participant.
Study NCT02444312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benefit-finding Writing Activity
Description: Caregivers will be instructed to write about the benefits of caring, considering things such as improved social relationship, appreciation of life and loved ones, and the positive consequences with respect to these.
Study NCT02444312 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Writing Activity
Description: The control group will be instructed to write number of things about the weather that day. Although the sentences can be as long or as short as they like, they will be encouraged to try and aim for about 3 or 4 sentences at least.
Study NCT04840407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHARP coach intervention
Description: The Coach provides guidance and support through four 45-60 minute in-home visits: Visit 1: to facilitate effective team communication, this visit is conducted, when possible, with the rehabilitation therapist, the patient/family, the direct care aide and the Coach, who jointly reviews the rehabilitation plan of care. Visits 2-4 include: discussion/observation of HHA/patient exercise repetition sessions, along with: 1) discussing falls prevention, signs of a recurrent stroke and when to call 911; 2) modeling motivation techniques, assessing adherence barriers and revising strategies for addressing them; and 3) identifying/ reporting signs of anxiety/depression. Additional coaching visits and calls may be scheduled as needed depending on the aide's progress in addressing barriers and the patient's progress toward rehabilitation goals.
Study NCT02578732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXA
Description: Schema:~1 cycle = 14 days \*\*It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG\*\*~Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)~* It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment~* Antiemetics will be administered as per standard institutional policy.
Study NCT01499914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza vaccination
Description: Influenza vaccination in patients with cystic fibrosis
Study NCT04226911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S&SEs
Description: S\&SEs:~As many sugar-containing products in the diet as possible should be replaced with S\&SE-containing products.~To ensure that a certain amount of S\&SE products is consumed every day, a fixed minimum amount of units for each individual is planned.
Study NCT04226911 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sugar
Description: Sugar group:~In the sugar group it is allowed to consume up to a certain number of units of sugar-containing products each day, corresponding to \< 10 E% added sugar.~The sugar group is not allowed to consume any S\&SE products.
Study NCT02989766 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education on Breast Feeding
Description: Subjects in the intervention arm will complete 3 activity sheets prenatally-study related.
Study NCT04128254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban Oral Tablet
Description: Apixaban is a kind of oral anticoagulant drugs used to prevent venous thromboembolism
Study NCT04128254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apixaban Oral Tablet
Description: Apixaban is a kind of oral anticoagulant drugs used to prevent venous thromboembolism
Study NCT00625807 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RR
Description: A well-validated 8 week stress reduction course. Classes meet once a week for 1.5 hours. Participants will be asked to perform stress reduction techniques each night for 20 minutes throughout the entire 8-week course. Stress reduction techniques use meditative techniques that focus primarily on inducing relaxation
Study NCT00625807 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBSR
Description: A well-validated 8 week stress reduction course. Classes meet once a week for 1.5 hours. Participants will be asked to perform stress reduction techniques each night for 20 minutes throughout the entire 8-week course. Stress reduction techniques use meditative techniques that focus primarily on inducing mindfulness
Study NCT02125188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Desmopressin 3ug/kg ivdrip before surgery
Study NCT02125188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline 100ml ivdrip before surgery
Study NCT01614509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intravitreal bevacizumab monotherapy
Description: The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle.
Study NCT01614509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab injection
Description: The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
Study NCT01584986 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ACP injections
Description: Peripheral blood-derived, ex vivo expanded autologous angiogenic cell precursors (ACPs)
Study NCT02993250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: Participants will receive AL-335 800 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
Study NCT03820193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Post-Operative Non Opioid Pain Protocol
Study NCT03820193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodon/Acetaminophen
Description: Traditionally used narcotic pain control
Study NCT03820193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Post-Operative Non Opioid Pain Protocol
Study NCT03820193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Post-Operative Non Opioid Pain Protocol
Study NCT03820193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Post-Operative Non Opioid Pain Protocol
Study NCT03820193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Post-Operative Non Opioid Pain Protocol
Study NCT00876278 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: *AT.Smart 46LC
Description: Primary implantation of \*AT.Smart 46 LC into the eye's capsular bag for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the \*AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
Study NCT02708277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: loop-shaped intrauterine contraceptive device
Description: Intrauterine contraceptive device can temporary protective layer between the endometrium wound during the most critical three weeks after the surgery to prevent adhesion reformation.
Study NCT02708277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intrauterine balloon (Cook Medical)
Description: The balloons used in this study is heart- shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to loop-shaped intrauterine contraceptive device.
Study NCT03057587 — intervention group
Intervention type: DEVICE
Intervention: NIRS Monitoring
Description: NIRS data will be collected throughout the surgery
Study NCT01482624 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronan (0.5%, 5 mg/10 ml)
Description: Standard arthroscopic meniscal surgery and add-on treatment with VISCOSEAL® SYRINGE. Single injection of Hyaluronan directly after arthroscopic procedure.
Study NCT01482624 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard arthroscopic meniscal surgery
Description: Standard arthroscopic meniscal surgery without add-on treatment.
Study NCT04602104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: low dose hMSC-Exos
Description: basic treatment and 7 times aerosol inhalation of hMSC-Exos (2.0\*10\^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
Study NCT04602104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: medium dose hMSC-Exos
Description: basic treatment and 7 times aerosol inhalation of hMSC-Exos (8.0\*10\^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
Study NCT04602104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dose hMSC-Exos
Description: basic treatment and 7 times aerosol inhalation of hMSC-Exos (16.0\*10\^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
Study NCT04602104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dosage 1of hMSC-Exos
Description: basic treatment and 7 times aerosol inhalation of hMSC-Exos (a quarter of MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
Study NCT04602104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dosage 2 of hMSC-Exos
Description: basic treatment and 7 times aerosol inhalation of hMSC-Exos (MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
Study NCT04602104 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: No hMSC-derived exosomes
Description: basic treatment and 7 times aerosol inhalation of normal saline (at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
Study NCT01193621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol, PET
Description: 1. Biodistribution study Intravenous 18F haloperidol(10 mCi) Dose injection two times before whole body PET scan~2. D2-receptor occupancy study Group Doses No. of subjects 1 0.5 mg 4 2 1 mg 4 3 3 mg 4~above doses will be administrated orally every 24 hours for 7 days.
Study NCT01938651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high field strength magnetic resonance imaging
Description: Undergo 7T MRI
Study NCT01938651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance spectroscopic imaging
Description: Undergo 31P MRS
Study NCT01938651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chemical exchange saturation transfer magnetic resonance imaging
Description: Undergo CEST-MRI
Study NCT02924857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chocolate Touch
Description: The Chocolate Touch™ Paclitaxel Coated Balloon Catheter is indicated for balloon dilatation, after appropriate vessel preparation as needed, of lesions in native superficial femoral or popliteal arteries up to 18 cm in length that are appropriate for angioplasty with balloon diameters from 3.5 mm to 6.0mm.
Study NCT02924857 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lutonix Drug Coated Balloon
Description: The Lutonix® 035 Drug Coated Balloon Catheter is indicated for improving luminal diameter for the treatment of obstructive de novo or non-stented restenotic lesions (≤ 18 cm in length) in native femoropopliteal arteries having reference vessel diameters of 4 mm to 6 mm.
Study NCT01375881 — intervention group
Intervention type: DRUG
Intervention: darunavir/ritonavir plus background regimen
Description: darunavir/ritonavir, oral use, in naive and experienced patients at approved dosages
Study NCT01584609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penumbra System with Separator 3D
Description: The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.
Study NCT01584609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Penumbra System alone
Description: The Penumbra System® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.
Study NCT02993250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: Participants will receive ODV 25 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
Study NCT02993250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV)
Description: Participants will receive SMV 75 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
Study NCT00187135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA
Description: All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). EMLA application has to be over at least 60 minutes and not to exceed 5 hours.
Study NCT03706378 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Reference 1
Description: Glucose contains 50g of available carbohydrates
Study NCT03706378 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Reference 2
Description: Glucose contains 50g of available carbohydrates
Study NCT03706378 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Reference 3
Description: Glucose contains 50g of available carbohydrates
Study NCT00187135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EMLA
Description: All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). EMLA application has to be over at least 60 minutes and not to exceed 5 hours.